We found that ZFP36/TTP was phosphorylated mainly in breast cancer cell lines, including ERBB2-amplified SKBR3, and demonstrated that lapatinib—also ERBB2 siRNA-reduced the abundance of the phosphorylated ZFP36/TTP in a dose-dependent manner. Here, ERBB2 is linked to breast cancer.